Amwill Health Care Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Amwill Health Care Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹111
Per ShareLot Size
1200 Shares
Minimum Investment
₹1,33,200
Issue Size
₹59.98 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
40%
QIB Quota
20%
NII Quota
40%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Amwill Health Care Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
97%
Promoter Holding (Post-Issue)
70.64%
Issue Type
Book Building - SME
ISIN
INE0U2L01017
About the Company
We are a derma-cosmetic development company, associated with contract manufacturers, distributor and third party product development agencies, which has enabled us in developing capabilities, in manufacturing, packaging and distribution. The core focus of our Company is on development of problem solving dermatological, cosmeceutical and aesthetical products, and therefore to direct all our efforts towards product formulation and development, we have outsourced key functions such as manufacturing, prototype development and distribution to third parties, for effective management and execution. The product portfolio of our Company is divided into two categories, namely, (i) development and contract manufacturing of generic dermatological solutions; and (ii) developing and formulating solutions to specific dermatological problem. Majority of the products marketed by us, were developed by our Promoter and Managing Director, Anand Gandhi, in the capacity of a sole proprietor of Amwill Healthcare.
Industry Overview
India's $14 billion beauty and personal care industry is on a roll thanks to online sales of beauty products, premiumisation, and an inclination towards organic and ethical brands. According to a report by research firm Euromonitor International, last year, with the presence of online retailers like Nykaa.com and Amazon.com, the beauty and personal care products category crossed $400 million in internet sales up from $100 million in 2014. The cosmetics sector will continue to expand, reflecting the changing market trends. In this era of digital dominance, the businesses that provide customers with a highly personalised experience will be the real trendsetters in the cosmetics sector. Boddess' focus on Al, AR, and skin and makeup diagnostic tools, for instance, has fuelled the growth of the beauty business. Personalised packaging is currently popular, with items like name-engraved lipstick and intensely hydrating moisturisers. Additionally, throughout the coming year, the brand will become more palpable, ensuring encounters both online and offline. Below are a few growth drivers which are the economy and culture are opening on a global level, there's an increase in the adoption of Western culture. Globalization helps in easing cross-border transactions and creates the desire to access new products and services.
Company History
Amwill Health Care Limited ("Company" or the "Issuer") was originally incorporated on August 21, 2017, under the name `Amwill Health Care Private Limited', pursuant to a certificate of incorporation dated August 22, 2017 issued by the Deputy Registrar of Companies, Karnataka at Bangalore. Further, our Company was converted into a public limited company pursuant to a resolution passed by our Board of Directors in their meeting held on December 28, 2023 and by the Shareholders in an Extraordinary General Meeting held on December 29, 2023 and a fresh certificate of incorporation dated January 25, 2024 was issued by the Registrar of Companies, Karnataka at Bangalore. Consequent to the conversion of our Company, the name of our Company was changed to `Amwill Health Care Limited'.
Products & Services
- The Company is a derma-cosmetic development company, associated with contract manufacturers, distributor and third party product development agencies, which has enabled it in developing capabilities, in manufacturing, packaging and distribution.
Growth Strategy
- Expand product portfolio and delivery systems to drive revenue growth.
- Diversifying and increasing penetration in untapped markets.
- Strengthen our marketing network.
Customer Base
Wholesaler and Retailer
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY24 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offer of 54,03,600* equity shares of face value of Rs. 10/- each ("Equity Shares") of the company at an offer price of Rs. 111 per equity share (including a share premium of Rs. 101 per equity share) for cash, aggregating Rs. 59.98 crores ("Public Offer") comprising a fresh issue of 44,03,600 equity shares aggregating Rs. 48.88 crores (the "Fresh Issue") and an offer for sale of 10,00,000 equity shares, comprising of 4,55,200 equity shares aggregating Rs. 5.05 crores by Bhavika Gandhi, 4,55,200 equity shares aggregating Rs. 5.05 crores by Isha Gandhi, 49,500 equity shares aggregating Rs. 0.55 crores by Shashikala and 40,100 equity shares aggregating Rs. 0.45 crores by Bhavya Gandhi (collectively, "The promoter Group Selling Shareholders" or "The Selling Shareholders" and such offer for sale of equity shares by the selling shareholders, the "Offer for Sale") aggregating Rs. 11.10 crores, out of which 2,71,200 equity shares of face value of Rs. 10/- each, at an offer price of Rs. 111 per equity share for cash, aggregating Rs. 3.01 crores was reserved for subscription by the market maker to the offer (the "Market Maker Reservation Portion"). The public offer less market maker reservation portion i.e. offer of 51,32,400 equity shares of face value of Rs. 10/- each, at an offer price of Rs. 111 per equity share for cash, aggregating Rs. 56.97 crores is hereinafter referred to as the "Net Offer". The public offer and net offer will constitute 27.01% and 25.66% respectively of the post-offer paid-up equity share capital of the company.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Extensive product portfolio supported by product formulation capabilities and dynamic advisory board of reputed dermatologists.
- Long standing presence through our Promoters with strong brand equity.
- Provision of high-quality product development through tie ups with contract manufacturers and prototype developers.
- Well experienced management team with proven project management and implementation skills.
- The company has appointed one of its Promoter Group entities, M/s. Amderma Healthcare LLP as a carrying and forwarding agent for storing, delivering and distributing its products. Consequently, the company derives all of its revenue from M/s. Amderma Healthcare LLP. Any non-performance or breach of covenants of the carrying and forwarding agreement executed with M/s. Amderma Healthcare LLP may adversely affect its business operations, profitability and cash flows.
- The company relies on third party contract manufacturers for manufacturing products of the Company.
- Its commercial success is largely dependent upon the company's ability to develop and devise problem solving dermacosmetic products. The company has developed a limited number of products since incorporation and therefore, its ability to innovate new products might be limited, which may have an adverse impact on its revenue and profitability.
- The company derives a significant portion of its revenue from certain of the company products. If sales volume or price of such products declines in the future, or if the company is unable to sell such products for any reason, its business, financial condition, cash flows and results of operations could be adversely affected.
- Its business and prospects may be adversely affected if the company is unable to maintain and grow the image of its brands. Further, pursuant to the Memorandum of Understanding dated March 31, 2020 executed between M/s. Amwill Healthcare and the Company ("Asset Transfer MoU"), its Promoter Anand Gandhi has transferred all the trademarks which were previously owned by M/s. Amwill Healthcare. The Company has made applications before the Registrar of Trademarks for registering the Asset Transfer MoU and change in ownership of the aforementioned trademarks, which are presently pending.